© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 13, 1004-1007,
July 2, 2003
© 2003 Oxford University Press
BRIEF COMMUNICATION |
Zinc Supplement Use and Risk of Prostate Cancer
Affiliations of authors: M. F. Leitzmann, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; M. J. Stampfer, W. C. Willett, E. L. Giovannucci, Departments of Epidemiology and Nutrition, Harvard School of Public Health, and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA; K. Wu, Department of Nutrition, Harvard School of Public Health; G. A. Colditz, Department of Epidemiology, Harvard School of Public Health, and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital.
Corresponding author: Michael F. Leitzmann, M.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6120 Executive Blvd., EPS-MSC 7232, Bethesda, MD 20892 (e-mail: leitzmann{at}mail.nih.gov).
ABSTRACT
The high concentration of zinc in the prostate suggests that zinc may play a role in prostate health. We examined the association between supplemental zinc intake and prostate cancer risk among 46 974 U.S. men participating in the Health Professionals Follow-Up Study. During 14 years of follow-up from 1986 through 2000, 2901 new cases of prostate cancer were ascertained, of which 434 cases were diagnosed as advanced cancer. Supplemental zinc intake at doses of up to 100 mg/day was not associated with prostate cancer risk. However, compared with nonusers, men who consumed more than 100 mg/day of supplemental zinc had a relative risk of advanced prostate cancer of 2.29 (95% confidence interval = 1.06 to 4.95; Ptrend = .003), and men who took supplemental zinc for 10 or more years had a relative risk of 2.37 (95% confidence interval = 1.42 to 3.95; Ptrend<.001). Although we cannot rule out residual confounding by supplemental calcium intake or some unmeasured correlate of zinc supplement use, our findings, that chronic zinc oversupply may play a role in prostate carcinogenesis, warrant further investigation.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Zinc Supplement Use and Risk of Prostate Cancer
- Cheryl A. Krone and Louis C. Harms
J Natl Cancer Inst 2003 95: 1556.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Zinc Supplement Use and Risk of Prostate Cancer
- Michael F. Leitzmann and Edward L. Giovannucci
J Natl Cancer Inst 2003 95: 1556-1557.[Extract] [Full Text] [PDF]
- Re: Zinc Supplement Use and Risk of Prostate Cancer
- Leslie C. Costello, Renty B. Franklin, Pei Feng, and Ming Tan
J Natl Cancer Inst 2004 96: 239-240.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Zinc Supplement Use and Risk of Prostate Cancer
- Michael F. Leitzmann and Edward Giovannucci
J Natl Cancer Inst 2004 96: 240-241.[Extract] [Full Text] [PDF]
- Re: Zinc Supplement Use and Risk of Prostate Cancer
- Ellen T. Chang, Maria Hedelin, Hans-Olov Adami, Henrik Grönberg, and Katarina A. Bälter
J Natl Cancer Inst 2004 96: 1108.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Zinc Supplement Use and Risk of Prostate Cancer
- Michael F. Leitzmann and Edward Giovannucci
J Natl Cancer Inst 2004 96: 1108-1109.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  C.-T. Han, N. W. Schoene, and K. Y. Lei Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1188 - C1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bilger, R. Sullivan, A. J. Prunuske, L. Clipson, N. R. Drinkwater, and W. F. Dove Widespread hyperplasia induced by transgenic TGF{alpha} in ApcMin mice is associated with only regional effects on tumorigenesis Carcinogenesis, September 1, 2008; 29(9): 1825 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yan, Y. Song, C. P. Wong, K. Hardin, and E. Ho Zinc Deficiency Alters DNA Damage Response Genes in Normal Human Prostate Epithelial Cells J. Nutr., April 1, 2008; 138(4): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. M. Shih, S. H. K. Wong, N. W. Schoene, and K. Y. Lei Suppression of Gadd45 Alleviates the G2/M Blockage and the Enhanced Phosphorylation of p53 and p38 in Zinc Supplemented Normal Human Bronchial Epithelial Cells Experimental Biology and Medicine, March 1, 2008; 233(3): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Lawson, M. E. Wright, A. Subar, T. Mouw, A. Hollenbeck, A. Schatzkin, and M. F. Leitzmann Multivitamin Use and Risk of Prostate Cancer in the National Institutes of Health-AARP Diet and Health Study J Natl Cancer Inst, May 16, 2007; 99(10): 754 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Giovannucci, Y. Liu, M. J. Stampfer, and W. C. Willett A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 203 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Chan, P. H. Gann, and E. L. Giovannucci Role of Diet in Prostate Cancer Development and Progression J. Clin. Oncol., November 10, 2005; 23(32): 8152 - 8160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Waters, S. Shen, L. T. Glickman, D. M. Cooley, D. G. Bostwick, J. Qian, G. F. Combs Jr, and J. S. Morris Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model Carcinogenesis, July 1, 2005; 26(7): 1256 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Giovannucci, Y. Liu, M. F. Leitzmann, M. J. Stampfer, and W. C. Willett A Prospective Study of Physical Activity and Incident and Fatal Prostate Cancer Arch Intern Med, May 9, 2005; 165(9): 1005 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Henrique, C. Jeronimo, M. O. Hoque, S. Nomoto, A. L. Carvalho, V. L. Costa, J. Oliveira, M. R. Teixeira, C. Lopes, and D. Sidransky MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1274 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Magda, P. Lecane, R. A. Miller, C. Lepp, D. Miles, M. Mesfin, J. E. Biaglow, V. V. Ho, D. Chawannakul, S. Nagpal, et al. Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell Lines Cancer Res., May 1, 2005; 65(9): 3837 - 3845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Rogers, D. Gunnell, P. M. Emmett, L. R. Glynn, D. B. Dunger, J. M. Holly, and and ALSPAC Study Team Cross-Sectional Associations of Diet and Insulin-Like Growth Factor Levels in 7- to 8-Year-Old Children Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Jarrard Does Zinc Supplementation Increase the Risk of Prostate Cancer? Arch Ophthalmol, January 1, 2005; 123(1): 102 - 103. [Full Text] [PDF]
|
|
|
|
|
|
E. T. Chang, M. Hedelin, H.-O. Adami, H. Gronberg, and K. A. Balter Re: Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, July 21, 2004; 96(14): 1108 - 1108. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Leitzmann and E. Giovannucci RESPONSE: Re: Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, July 21, 2004; 96(14): 1108 - 1109. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mares, T. L. La Rowe, and B. A. Blodi Doctor, What Vitamins Should I Take for My Eyes? Arch Ophthalmol, April 1, 2004; 122(4): 628 - 635. [Full Text] [PDF]
|
|
|
|
|
|
L. C. Costello, R. B. Franklin, P. Feng, and M. Tan Re: Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, February 4, 2004; 96(3): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Leitzmann and E. Giovannucci RESPONSE: Re: Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, February 4, 2004; 96(3): 240 - 241. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Krone and L. C. Harms Re: Zinc Supplement Use and Risk of Prostate Cancer J Natl Cancer Inst, October 15, 2003; 95(20): 1556 - 1556. [Full Text] [PDF]
|
|